Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

AdCTLA4-Ig Improves Induction of Transplantation Tolerance to the Allogeneic Skin Allograft in Mice

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Gut Microbes Enlarged the Protective Effect of Transplanted Regulatory B Cells on Rejection of Cardiac Allografts.

Improvement of Transplantation Tolerance of Skin Allograft by Infusion of Donor Bone Marrow Cells and Its Mechanism

[Experimental Study of Immunological Tolerance Induced by Cytotoxic T Lymphocyte-Associated Antigen 4 Immunoglobulin in Fresh Bone Allografts].

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Induction of mixed chimerism and cardiac transplantation tolerance by CTLA-4 Ig adenovirus gene therapy combined with infusion of donor cells in allogeneic rats

Combined Treatment of Allograft Recipients with CTLA-4 Ig and Anti-Icam-1 Mab Plus Transfusion of Donor-Specific DC Progenitors

In Vitro Study of Immune Tolerance Induced by CTLA4–Ig in Bone Transplantation: the Effect on Cell Proliferation Stimulated by Lymphocytes and Bone Supernatant

Study on the Induction of Transplantation Tolerance in Mice by Continuous Infusion of Donor Spleen Cells and Its Mechanisms

Anti-ICAM-1 Antibody and CTLA-4Ig Synergistically Enhance Immature Dendritic Cells to Induce Donor-Specific Immune Tolerance in Vivo

Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.

Immune Tolerance of Allogeneic T Cells Induced by Dendritic Cells Genetically Engineered to Express Iκ Bα Mutant

[Influence of Donor Treg Cells on GVHD and GVL Effects after Allogeneic Bone Marrow Transplantation in Mice].

The Role of IL-4 in the Induction of Tolerance by Pretransplant Infusion of Donor Liver Nonparenchymal Cell

Induction of Immunotolerance in Mice after Skin Allotransplantation by Subcutaneous Injection of Bone Marrow

Cytotoxic T Lymphocyte-associated Protein 4 Acts on Local Draining Lymph Nodes in the Allogeneic Abdominal Skin Flap of a Rat Model to Extend Its Survival

Combined Use of Vitamin D-derived Drug and DBMC to Induce Tolerance on Heterotopic Rat Cardiac Allograft

Effects of short-course immunosuppression on chimerism and tolerance indhuced by bone marrow transplantation without cytoreductive conditioning

The effect of FK506 and adenovirus containing CTLA4Ig gene on the induction of transplantation tolerance

Development of the Model of Long Term Donor Specific Skin Allograft Survival Induced by Pretransplant Infusion of Donor Liver Nonparenchymal Cells